 |
 |
The 1994 UPF newsletter #4, part 1, page 8 paragraph about information from Dr. William Tatton expressed his hope that the deprenyl patch would soon be available (since only abot 5% of the oral deprenyl makes it to the brain. This sounds very prudent as a method of administering. Does anyone know whether such a transcutaneous patch is being developed for market? What about transcutaneous (through the skin) delivery of other PD medications? Has this been tried with l-dopa? Would seem to me that patch application over the corotid artery path lowest on the neck might be better than elsewhere. Are there any drug companies receiving this list info? could sending it gratis be initiated? Ron <[log in to unmask]> Ronald F. Vetter